Teva Pharmaceuticals Industries Ltd has entered a co-marketing agreement with Syqe Medical Ltd, a medicinal plant inhaler developer.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

According to the agreement, Teva Pharmaceuticals will be responsible to market cannabis with Syqe Medical’s selective-dose medicinal plant inhaler.

The agreement allows the two partners to introduce cannabis inhaler for pain management in Israel.

Boston Children’s Hospital and GE Healthcare Ltd, a medical device company, have entered an agreement to further advance the diagnosis of brain diseases in children.

According to the agreement, both the partners will develop and commercialise digital diagnostic solutions to diagnose brain disorders.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Lab Genomics, a molecular diagnostics products provider, plans to raise $8.54m through the private placement of convertible bonds due 2 December 2021.

"According to the agreement, both the partners will develop and commercialise digital diagnostic solutions to diagnose brain disorders."

The company plans to invest the funds for general corporate purposes.

Annidis Corporation, a retinal imaging technology product provider, plans for a private placement of 43 million of its common stock shares to raise $1.62m.

The company intends to use the funds to increase the working capital.

Image: Teva Pharmaceuticals Industries Ltd has entered a co-marketing agreement with Syqe Medical. Image courtesy of Wikimedia Commons.